基于荷兰实施首年结果的HPV宫颈癌筛查成本效果:一项模型研究
该模型研究利用荷兰最新流行病学与筛查数据更新MISCAN模型,比较旧细胞学筛查与新hrHPV筛查项目的成本效果。结果显示,hrHPV筛查使宫颈癌死亡率降低4%、发病率降低1%,无CIN2及以上病变者的阴道镜转诊增加172%,但QALY增加13%,总成本降低21%,每获得一个QALY的成本为€12,225,较细胞学筛查的€22,678低46%,且在所有敏感性分析中均保持更优成本效果。
要点
- hrHPV筛查较细胞学筛查使宫颈癌死亡率降低4%、发病率降低1%。
- 无CIN2及以上病变者的阴道镜转诊增加172%,但QALY增加13%。
- hrHPV筛查每QALY成本€12,225,较细胞学€22,678低46%,所有敏感性分析中均更优。
核心结论
- hrHPV筛查项目比细胞学筛查项目更有效且更具成本效果。
- 应考虑当前分诊策略的替代方案以减少不必要的转诊。
研究设计与样本
- 基于模型的成本效果分析,使用荷兰最新流行病学与筛查数据更新MISCAN微模拟模型。
- 模拟对象为荷兰30岁未接种疫苗女性,终身随访。
- 模拟旧细胞学筛查与新hrHPV筛查两个项目,采用各自观察到的筛查行为和成本。
- 对筛查行为、效用损失和贴现率进行敏感性分析。
主要发现
- 新hrHPV筛查项目较旧项目使宫颈癌死亡率降低4%、发病率降低1%。
- 无CIN2及以上病变者的阴道镜转诊增加172%。
- QALY增加13%。
- 总成本降低21%,主要因筛查测试次数减少。
- 每获得一个QALY,hrHPV项目成本€12,225,细胞学项目成本€22,678,hrHPV项目低46%,且在所有敏感性分析中均保持更优成本效果。
临床怎么用
- 作者认为应考虑当前分诊策略的替代方案以降低不必要的转诊。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aim to compare the cost-effectiveness of the old cytology programme with the new high-risk human papillomavirus (hrHPV) screening programme, using performance indicators from the new Dutch hrHPV screening programme. DESIGN: Model-based cost-effectiveness analysis. SETTING: The Netherlands. POPULATION: Dutch 30-year-old unvaccinated females followed up lifelong. METHODS: We updated the microsimulation screening analysis (MISCAN) model using the most recent epidemiological and screening data from the Netherlands. We simulated both screening programmes, using the screening behaviour and costs observed in each programme. Sensitivity analyses were performed on screening behaviour, utility losses and discount rates. MAIN OUTCOME MEASURES: Cervical cancer incidence and mortality rates, number of screening tests and repeat tests, colposcopy referrals by lesion grade, costs from a societal perspective, quality-adjusted life years (QALYs) gained and cost-effectiveness. RESULTS: The new Dutch cervical cancer screening programme decreased the cervical cancer mortality by 4% and the incidence by 1% compared with the old programme. Colposcopy referrals of women without cervical intra-epithelial neoplasia grade 2 or worse, increased by 172%, but 13% more QALYs were still achieved. Total costs were reduced by 21%, mainly due to fewer screening tests. Per QALY gained, the hrHPV programme cost 46% less (€12,225) than the cytology programme (€22,678), and hrHPV-based screening remained more cost-effective in all sensitivity analyses. CONCLUSIONS: The hrHPV-based screening programme was found to be more effective and cost-effective than the cytology programme. Alternatives for the current triage strategy should be considered to lower the number of unnecessary referrals. TWEETABLE ABSTRACT: First results after implementation confirm that HPV screening is more cost-effective than cytology screening.
引用
- Jansen E, Naber SK, Aitken CA, et al. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. BJOG. 2020. PMID: 32638462. doi:10.1111/1471-0528.16400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。